<img src="https://ml.globenewswire.com/Resource/Download/23e4046d-dcf9-4dd1-945e-461e98a27d15?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Full Logo - OKYO .jpg" alt="OKYO Pharma LTD"/>LONDON and NEW YORK, July 22, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- OKYO Pharma Limited (Nasdaq: <a href="https://www.globenewswire.com/Tracker?data=EaIZsWh3V2VuFDaF-gHxinFDLXYYoky9-MQ5oG5zc1N_zzrhry6t9tv74IUCjqbb7EqYHkZhyOAfs8KjAt0oEO1IKQhPwPdvCAc8cIDILGpEGP7y3TMfTGTHC__L_NEi" rel="nofollow" target="_blank" title="OKYO">OKYO</a>), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company’s ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares. About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP. For further information, please visit <a href="https://www.globenewswire.com/Tracker?data=HgWtwnWUw6XeI7hxhaA5BhO6s12NEErvVuCOgSALjCwQHWD2QS_s-j4KL1BD7ivL9ENAPgRFEBgeRukQVq5AOSFmbO-1AGiyLD4T1t6hfG8=" rel="nofollow" target="_blank" title="www.okyopharma.com">www.okyopharma.com</a>. For further inquiries: OKYO Pharma Ltd Paul Spencer Business Development and Investor Relations +44 (0) 207 495 2379 Email: <a href="https://www.globenewswire.com/Tracker?data=Fn99BSQtyzal8XBEUYZEu1UH_Lk9CaC510HsMZ-ROH_UtC2P1jHSWss5mOUSxM30ISU33pOH-g5KEcfHYPEH4ybdmgoE5stMRHfhkVT_uH4=" rel="nofollow" target="_blank" title="info@okyopharma.com">info@okyopharma.com</a> <img alt="" src='https://ml.globenewswire.com/media/NTk2M2Y1M2EtNGU0MC00NjZjLTgwYjYtNDc3OTQ4M2NhZjg1LTEyMTI5OTYtMjAyNi0wNy0yMi1lbg==/tiny/OKYO-Pharma-LTD.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn